ORY — ORYZON Genomics SA Balance Sheet
0.000.00%
- €265.74m
- €248.35m
- 11
- 22
- 81
- 27
Annual balance sheet for ORYZON Genomics SA, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 39.6 | 28.7 | 21.3 | 12.3 | 5.62 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 2.46 | 3.78 | 3.84 | 2.01 | 3.13 |
| Total Inventory | |||||
| Total Current Assets | 42.4 | 32.6 | 25.2 | 14.3 | 8.75 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 0.644 | 0.682 | 0.611 | 0.481 | 0.356 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 94.1 | 95.4 | 104 | 107 | 109 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 7.69 | 8.67 | 18.7 | 16.4 | 11.7 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 18.2 | 24.1 | 31.1 | 25.1 | 21.7 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Other Equity | |||||
| Total Equity | 75.9 | 71.3 | 72.6 | 81.8 | 87 |
| Total Liabilities & Shareholders' Equity | 94.1 | 95.4 | 104 | 107 | 109 |
| Total Common Shares Outstanding |